| Stereochemistry | UNKNOWN |
| Molecular Formula | C18H36Cl2N4O2 |
| Molecular Weight | 411.41 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 4 |
| E/Z Centers | 0 |
| Charge | 2 |
SHOW SMILES / InChI
SMILES
OC(CCl)CN1CC[N+]2(CC1)CC[N+]3(CCN(CC(O)CCl)CC3)CC2
InChI
InChIKey=UVYDWIMQPVNRJN-UHFFFAOYSA-N
InChI=1S/C18H36Cl2N4O2/c19-13-17(25)15-21-1-5-23(6-2-21)9-11-24(12-10-23)7-3-22(4-8-24)16-18(26)14-20/h17-18,25-26H,1-16H2/q+2
| Molecular Formula | C18H34Cl2N4O2 |
| Molecular Weight | 409.394 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Prospidium is a diazoniadispiro(5.2.5.2)hexadecane derivative patented by All-Union Scientific-Research Chemical-Pharmaceutical Institute as an antitumor agent that does not inhibit hematopoiesis. In preclinical models, The injection of Prospidium to thyroidectomized and hypophysectomized rats inhibited tumor growth to a greater extent than in intact rats. Larynx and lung cancer, lymphogranulomatosis, leucosis, etc. can be successfully treated with Prospidium at doses of 60-120 mg daily.
